Delivery Order SPE2DR25D9237-SPE2DR26FKSQ5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,730.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 mL vials. This firm fixed-price delivery order, issued on November 7, 2025, is scheduled for ultimate completion by December 2, 2025, and carries no set-aside designation, indicating the award was made through open competition. The order is issued under DMS...
- The Defense Logistics Agency awarded a delivery order valued at $1,243.50 to DMS Pharmaceutical Group Inc. on October 30, 2025, for the supply of EXPAREL (133 mg/10 mL vial, 10 mL quantity). EXPAREL is a liposomal bupivacaine formulation used for infiltration and nerve block anesthesia in surgical settings. The delivery order carries a firm fixed-price structure with no set-aside designation, indicating the award was made through unrestricted competition. Performance is scheduled for...
- The Defense Logistics Agency awarded a delivery order valued at $7,691.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EXPAREL (133 mg/10 mL vial). This firm fixed-price delivery order, issued on October 28, 2025, with an ultimate completion date of November 19, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency awarded a $5,021.26 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EXPAREL 266 mg/20 ml vials. The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, indicating the vendor competed in an unrestricted federal procurement environment. This award falls under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $3,046.10 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 mL vials. The award, issued on October 21, 2025, with an ultimate completion date of November 12, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This...
- The Defense Logistics Agency awarded a delivery order valued at $3,730.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 ml vials. This firm fixed-price delivery order, issued on October 30, 2025, with an ultimate completion date of November 21, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is...
- The Defense Logistics Agency (DLA) awarded a $3,014.44 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 mL vials. The delivery order, issued on October 24, 2025, with an ultimate completion date of November 17, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award is issued under DMS...
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $9,044.22 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 mL vials. This delivery order, awarded on October 20, 2025, represents one of numerous pharmaceutical procurement actions issued to the vendor during October 2025. The award carries no set-aside designation, demonstrating DMS Pharmaceutical Group's...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $3,108.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL (liposomal bupivacaine) 133 mg/10 mL vials. This delivery order, issued on November 4, 2025, with an ultimate completion date of November 26, 2025, carries no set-aside designation, indicating that DMS Pharmaceutical Group competed successfully in an...
- The Defense Logistics Agency (DLA) awarded a $20,085.04 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. The delivery order, issued on October 31, 2025, with an ultimate completion date of November 24, 2025, was made without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement....
- SPE2DR25D9237Indefinite Delivery Contract
- SPE2DR25D9237-SPE2DR26FKSQ5Delivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $1,538.21 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EXPAREL (133 mg/10 mL vial). This delivery order, issued on November 7, 2025, with an ultimate completion date of December 2, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. EXPAREL is a liposomal bupivacaine formulation used for surgical anesthesia and pain management, reflecting the specialized pharmaceutical products within DMS Pharmaceutical Group's portfolio. This delivery order is issued under DMS Pharmaceutical Group's recently awarded Indefinite Delivery Contract (IDC) designated SPE2DR under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying comprehensive pharmaceutical products—including branded and generic prescription drugs, biologics, and medical consumables—to support Department of Defense healthcare operations globally across military medical facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 11/7/25 |